



CONTINUING MEDICAL EDUCATION

Harrington Heart & Vascular Institute CINEMA Symposium: Harmonizing Guidelines for Patients with Chronic Kidney Disease, Type 2 Diabetes and Cardiovascular Disease – 59216-58177

Date: June 8, 2023

Time: 7:00 PM-8:00 PM

Online

*Aparna Padiyar, MD; Mahboob Rahman, MD; Karen Monheim, MD; Ewa M Gross-Sawicka, MD, PhD;
Sanjay Rajaopalan, MD; Peter Pronovost, MD, PhD; Ian J Neeland, MD; Caitlin L Omoregie, PA-C;*

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify patients with type 2 diabetes mellitus at high risk for incidence and progression of chronic kidney disease and cardiovascular disease events.
- 2 Describe risk for CKD progression and CVD mortality using the KDIGO heat map.
- 3 Describe FDA-approved indications for use of non-steroidal MRA, SGLT2 inhibitor, and GLP-1 receptor agonists to reduce risk for CKD and CVD.
- 4 Identify 3 areas of agreement between nephrology, endocrinology, and cardiology guidelines.
- 5 Identify 3 gaps in knowledge and practice between nephrology, endocrinology, and cardiology guidelines.
- 6 Describe 3 ways that University Hospitals can address these gaps to improve knowledge and practice in the care for patients with chronic kidney disease in type 2 diabetes mellitus.
- 7 Describe 3 ways that University Hospitals can address these gaps to improve knowledge and practice in the care for patients with chronic kidney disease in type 2 diabetes mellitus.

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A display fee has been provided by Novo Nordisk, Bayer, Boehringer Ingelheim, Astra Zeneca, Novartis, and Amgen. Grant funds were received by Bayer.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Sanjay Rajagopalan, MD	Course Director, Faculty	Consulting Fee-Novio Nordisk - 08/29/2022
Sadeer Al-Kindi, MD	Faculty	Nothing to disclose - 10/12/2022
Revital Gorodeski Baskin, MD	Faculty	Nothing to disclose - 08/08/2022
Ewa M Gross-Sawicka, MD, PhD	Faculty	Nothing to disclose - 06/01/2023



SCHOOL OF MEDICINE
CASE WESTERN RESERVE
UNIVERSITY

Karen Monheim, MD	Faculty	Nothing to disclose - 05/30/2023
Caitlin L Omoregie, PA-C	Faculty	Consulting Fee-Dexcom Consulting Fee-Boehringer Ingelheim Vetmedica GmbH - 06/05/2023
Aparna Padiyar, MD	Faculty	Grant or research support-Bayer Corporation Stocks or stock options, excluding diversified mutual funds-Acadia Pharmaceuticals Stocks or stock options, excluding diversified mutual funds-Amgen Stocks or stock options, excluding diversified mutual funds-Amgen Stocks or stock options, excluding diversified mutual funds-Boston Scientific Corporation Stocks or stock options, excluding diversified mutual funds-Edwards Lifesciences LLC Stocks or stock options, excluding diversified mutual funds-GlaxoSmithKline Stocks or stock options, excluding diversified mutual funds-Guardant Health Inc Stocks or stock options, excluding diversified mutual funds-Jazz Pharmaceuticals Stocks or stock options, excluding diversified mutual funds-Johnson and Johnson Stocks or stock options, excluding diversified mutual funds-Kala Pharmaceuticals Stocks or stock options, excluding diversified mutual funds-Merck and Company, Inc. Stocks or stock options, excluding diversified mutual funds-Pfizer, Inc. Stocks or stock options, excluding diversified mutual funds-Regeneron Pharmaceuticals Stocks or stock options, excluding diversified mutual funds-Zimmer Biomet Holdings - 04/19/2023
Peter Pronovost, MD, PhD	Faculty	Nothing to disclose - 06/02/2023
Mahboob Rahman, MD	Faculty	Grant or research support-Bayer Corporation (Relationship has ended) Grant or research support-Duke Clinical Research Institute Honoraria-Relypsa (Relationship has ended) Honoraria-Reata (Relationship has ended) Honoraria-Bayer Corporation (Relationship has ended) Consulting Fee-Barologics (Relationship has ended) - 07/15/2022
Ian J Neeland, MD	Faculty, Other Planning Committee Member	Consulting Fee-Merck and Company, Inc. (Relationship has ended) Consulting Fee-Boehringer Ingelheim Consulting Fee-Nestle Health Sciences Consulting Fee-Bayer Corporation - 02/28/2023
Janice Friswold, Ms.	Other Planning Committee Member	Nothing to disclose - 09/14/2022
Diane Gorbey, RN, CNS	Other Planning Committee Member	Nothing to disclose - 02/20/2023
Judith Mackall, MD	Other Planning Committee Member	Consulting Fee-Abbott Laboratories - 04/24/2023